A PROSPECTIVE, MULTIPARAMETRIC BIOMARKER STUDY TO IDENTIFY PREDICTORS OF TREATMENT RESPONSE AND RESISTANCE IN PATIENTS WITH EGFR-MUTATED NON-SMALL-CELL LUNG CANCER RECEIVING MAINTENANCE THERAPY WITH EITHER AFATINIB OR PEMETREXED WITH THE AIO-TRK-0114 STUDY (MARBLE):